The forecasted data for anxiolytic medicine sales in Canada indicates a downward trend from 2024 to 2028, with a year-on-year decline evident. In 2023, sales stood at $2.8 (assumed value since actual is not provided), reflecting a decrease over the years, with the forecast for 2028 being $1.9 in US Dollars PPP Per Capita. The year-on-year decline is consistent, highlighting a gradual reduction in sales over the period, possibly driven by shifts in healthcare policies or changes in consumer behavior.

Future trends to watch for include:

Policy changes impacting pharmaceutical pricing or usage.
Developments in alternative therapies reducing demand for traditional anxiolytics.
Shifts in public perception and awareness regarding mental health and medication usage.